长春高新(000661) - 2015 Q3 - 季度业绩预告

Financial Performance - The net profit attributable to shareholders is expected to increase by 65.49% to 80.27%, with an estimated profit of between 280 million to 305 million CNY[3] - Basic earnings per share are projected to be approximately 2.13 to 2.32 CNY, compared to 1.29 CNY in the same period last year[3] - The increase in net profit is primarily due to the growth in profits from subsidiary pharmaceutical companies and an increase in revenue from real estate development projects[5] Financial Reporting - The performance forecast has not been audited by a registered accountant[4] - The financial data is based on preliminary calculations by the company's finance department, with detailed financial data to be disclosed in the Q3 report[6] - The performance forecast period is from January 1, 2015, to September 30, 2015[3] Investor Awareness - The company emphasizes the importance of investors being aware of investment risks[6] - The announcement was made by the board of directors on October 9, 2015[8]